The Food and Drug Administration rejected ivonescimab, a lung cancer drug invented by Chinese drugmaker Akeso Biopharma and licensed to Summit Therapeutics, a Florida company.
Summit disclosed the decision on Sunday. The company had sought approval for patients with advanced lung cancer who had already tried targeted treatments.
The FDA rejected the drug because it failed to show a statistically significant benefit in extending patients' lives in the global clinical trial underlying Summit's application. The trial compared patients receiving ivonescimab plus chemotherapy against those receiving chemotherapy alone. While the drug delayed cancer progression in the study, it did not extend survival.
Summit argued that slow enrollment in the trial explained the lack of life extension data. The company submitted additional analyses of longer-term patient outcomes that were not part of the original research plan, but these submissions did not persuade regulators to approve the drug.
Ivonescimab had raised hopes as a symbol of China's drug development capabilities. The drug is being tested in additional cancers including colon, bladder, and breast tumors.